Search clinical trials for: Budesonide, Formoterol Fumarate Drug Combination

Total 6147 results

AstraZeneca

Completed

Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations

Asthma

Netherlands
AstraZeneca

Completed

Prevention of Asthma Relapse After Discharge From Emergency (PARADE)

Asthma

Canada
AstraZeneca

Completed

MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults

Asthma

Denmark, Finland, Norway
AstraZeneca

Completed

STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma

Asthma

Croatia, Czech Republic, Latvia, Lithuania, Portugal, Slovakia, Greece, Iceland, Slovenia, Chile
Elpen Pharmaceutical Co. Inc.

Completed

Evaluation of the Effectiveness and Quality of Life With the Administration of the Fixed Combination of Budesonide Formoterol in Greek Patients With Asthma During Routine Clinical Practice. (BOREAS)

Quality of Life | Asthma

Greece
Boston Children's Hospital
Brigham and Women's Hospital

Terminated

Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma

Exercise Induced Asthma

United States
Temple University

Unknown

Effect of Symbicort on Sleep Quality in Patients With Emphysema

Emphysema | Poor Sleep Quality

United States
Assistance Publique - Hôpitaux de Paris

Completed

Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation (alloforb)

Bronchiolitis Obliterans | Allogeneic Stem Cell Transplantation

France
AstraZeneca

Completed

Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting

Asthma

Netherlands
AstraZeneca

Completed

Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma

Asthma

Japan
AstraZeneca

Completed

Local Phase 4 Pan-European SMART Study

Asthma

Italy, Sweden, France, Russian Federation, Spain, United Kingdom, Germany, Finland, Norway, Belgium, Netherlands, Greece, Ireland, Iceland
University of Dundee
AstraZeneca; NHS Tayside

Completed

Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial (MUSIC)

Chronic Obstructive Pulmonary Disease

United Kingdom
Hull University Teaching Hospitals NHS Trust

Completed

Effect on Adrenal Function of Budesonide Versus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United Kingdom
Hat Yai Medical Education Center

Completed

Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down Asthma

Asthma

Thailand
AstraZeneca

Recruiting

Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol) (CHOROS ORION)

Chronic Obstructive Pulmonary Disease

Italy
AstraZeneca

Completed

A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®

Asthma

Sweden, France, United Kingdom, Germany, Denmark, Spain
SkyePharma AG

Completed

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

Asthma

United States, Puerto Rico
Pearl Therapeutics, Inc.

Completed

A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose

Chronic Obstructive Pulmonary Disease

United States
UCSF Benioff Children's Hospital Oakland
National Cancer Institute (NCI)

Completed

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back

Skin Carcinoma

United States
Zhujiang Hospital

Unknown

Differences of Small Airways Function Between Chronic Obstructive Pulmonary Disease(COPD) and Asthma-copd Overlap(ACO)

Quality of Life | Pulmonary Disease, Chronic Obstructive | Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome | Small Airway Disease

China
Zhujiang Hospital

Unknown

Change of Lung Function After Exercise in Patients With Chronic Obstructive Pulmonary Disease

Quality of Life | Pulmonary Disease, Chronic Obstructive | Exercise | Lung Function Decreased

China
Zhujiang Hospital

Unknown

Small Airways Evaluation and Treatment

Pulmonary Disease，Chronic Obstructive;

China
British Columbia Cancer Agency
AstraZeneca

Completed

Studying Genes in Blood and Lung Fluid Samples From Patients With Chronic Obstructive Pulmonary Disease With or Without a Previous Diagnosis of Lung Cancer or With Asthma Treated With Budesonide and Formoterol

Lung Cancer | Precancerous Condition

Canada
AstraZeneca

Completed

Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients (MIA)

Exercise Induced Asthma

Sweden, Norway
Pearl Therapeutics, Inc.

Completed

Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects

Chronic Obstructive Pulmonary Disease

China
Sunovion

Completed

Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
AstraZeneca
QuintilesIMS, Inc.

Withdrawn

To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease (ASTUTE)

Chronic Obstructive Pulmonary Disease
AstraZeneca

Completed

Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma

Asthma

United States
Sunovion

Completed

To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD

Chronic Obstructive Pulmonary Disease | Emphysema | Chronic Bronchitis

United States
Organon and Co
Novartis

Completed

Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)

Asthma
AstraZeneca

Active, not recruiting

Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece (TRIAENA)

Pulmonary Disease, Chronic Obstructive (COPD)

Greece
GlaxoSmithKline

Completed

CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.

Asthma

Canada, Bulgaria, Estonia, Spain, Netherlands, Germany, Australia, Austria, Belgium, Finland, Ireland, Latvia, Macedonia, The Former Yugoslav Republic of, New Zealand, United Kingdom
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers (Reco-Pilot)

Asthma

Finland
AstraZeneca

Completed

Comparison Between Symbicort® and Prednisolone in COPD (SPACE)

Chronic Obstructive Pulmonary Disease

Sweden, Germany, Norway, Denmark, Finland
Novartis
Schering-Plough

Completed

Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma

Asthma

United States, Colombia, Peru
Organon and Co
Novartis

Completed

Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED)

Asthma
AstraZeneca

Completed

Symbicort Onset of Action 2

Asthma
Intech Biopharm Ltd.

Completed

A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block

Asthma | Chronic Obstructive Pulmonary Disease (COPD)
University of Alberta

Recruiting

Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use

Healthy

Canada
Boehringer Ingelheim

Completed

Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Dey

Completed

A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
SkyePharma AG

Completed

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma

Asthma

United States, Canada
AstraZeneca

Completed

DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults

Asthma

Germany
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

COPD
AstraZeneca

Not yet recruiting

Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD (COnCORD)

Chronic Obstructive Pulmonary Disease (COPD)
Washington University School of Medicine
National Institutes of Health (NIH); National Center for Advancing Translational...

Recruiting

Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers

Asthma | Nonadherence, Medication

United States
AstraZeneca

Completed

SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults

Asthma

Canada
Intech Biopharm Ltd.

Completed

A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block

Asthma | COPD

Taiwan
National Jewish Health

Completed

Sub-Sensitivity to Long-Acting Bronchodilators (LABA)

Asthma

United States
SkyePharma AG

Completed

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

Asthma

United States, Canada

3

Subscribe